JAZZ
PHARMACEUTICAL PREPARATIONSJazz Pharmaceuticals plc - Ordinary Shares (JAZZ) [ST]
www.jazzpharmaceuticals.com ↗▼ 0.41%
prev close
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Congressional Trades
2
All tracked trades
Members Trading
1
Unique members
Net Activity
+0
1 buys · 1 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2023-07-12 | JAZZJazz Pharmaceuticals plc - Ordinary Shares | Sell | $15,001 - $50,000 | 963d ago | — | |
| 2023-03-06 | JAZZJazz Pharmaceuticals plc - Ordinary Shares | Buy | $15,001 - $50,000 | 1081d ago | — |
2023-07-12
Daniel Goldman
JAZZ
Amount
$15,001 - $50,000
Filed
963d ago
2023-03-06
Daniel Goldman
JAZZ
Amount
$15,001 - $50,000
Filed
1081d ago
Recent News
Powered by Polygon.io
Artios Strengthens Leadership Team to Accelerate Late-Stage Development of Potential First-in-Class Oncology Pipeline
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?
Zymeworks Announces Participation in Upcoming Investor Conferences
Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial
Trade Timeline
Congressional activity, newest first
Daniel Goldman
2023-07-12 · Sale
$15,001 - $50,000
Daniel Goldman
2023-03-06 · Purchase
$15,001 - $50,000